CoChat
Sign Up
Cited by 22Sarcoma Diagnosis and TreatmentBone Metabolism and DiseasesBone Tumor Diagnosis and Treatments

Interaction gene set between osteoclasts and regulatory CD4+ T cells can accurately predict the prognosis of patients with osteosarcoma

Open access
Li, Feicui, Tang, Haijun, Luo, Xiaoting, Li, Xiangde, Luo, Kai, Liu, Shangyu, Liang, Jiming, Liao, Shijie +5 more·2023·Cancer Science
DOI 10.1111/cas.15821PMC PMC10323104
Open this paper in CoChat — free accountOpen PDF

Abstract

Osteoclasts (OCs) and regulatory CD4+ T cells (CD4+Tregs) are important components in the tumor microenvironment (TME) of osteosarcoma. In this study, we collected six osteosarcoma samples from our previous study (GSE162454). We also integrated a public database (GSE152048), which included single cell sequencing data of 11 osteosarcoma patients. We obtained 138,192 cells and then successfully identified OCs and CD4+Tregs. Based on the interaction gene set between OCs and CD4+Tregs, patients from GSE21257 were distinguished into two clusters by consensus clustering analysis. Both the tumor immune microenvironment and survival prognosis between the two clusters were significantly different. Subsequently, five model genes were identified by protein–protein interaction network based on differentially upregulated genes of cluster 2. Quantitative RT‐PCR was used to detect their expression in human osteoblast and osteosarcoma cells. A prognostic model was successfully established using these five genes. Kaplan–Meier survival analysis found that patients in the high‐risk group had worse survival (p = 0.029). Therefore, our study first found that cell–cell communication between OCs and CD4+Tregs significantly alters TME and is connected to poor prognosis of OS. The model we constructed can accurately predict prognosis for osteosarcoma patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.15821

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treg cells secrete immunosuppressive cytokines such as IL-10, IL-35, and TGF-β to inhibit the activity of effector T cells, and inhibit the formation of osteoclasts through direct cell contact-dependent manners.

    “They secrete immunosuppressive cytokines such as IL-10, IL-35, and TGF-β to inhibit the activity of effector T cells, and inhibit the formation of osteoclasts through direct cell contact-dependent manners [34].”

    From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [34]

    The Discussion (page unavailable) says CD4+ regulatory T cells contribute to immunosuppression by secreting cytokines. It does not identify IL-10, IL-35, or TGF-β as cytokines secreted by those cells, or say that they inhibit osteoclast formation through direct cell contact; its mention of IL-10 concerns osteoclasts. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Interaction of CD4+ Tregs and osteoclasts significantly alters TME and is connected to poor prognosis of osteosarcoma.

    “Interaction of CD4+ Tregs and osteoclasts significantly alters TME and is connected to poor prognosis of osteosarcoma [34].”

    From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [34]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. [2]Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and metastasis. Front Oncol. 2021; 11: 780264. 34956899 PMC8702962
  2. [3]Kager L, Tamamyan G, Bielack S. Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2017; 13: 357‐ 368. 27651036
  3. [4]Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021; 18: 609‐ 624. 34131316
  4. [5]Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021; 500: 1‐ 10. 33359211
  5. [6]Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019; 79: 4557‐ 4566. 31350295 PMC6744958
  6. [7]Liu Y, Feng W, Dai Y, et al. Single‐cell Transcriptomics reveals the complexity of the tumor microenvironment of treatment‐naive osteosarcoma. Front Oncol. 2021; 11: 709210. 34367994 PMC8335545
  7. [8]Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells. 2020; 9: 1‐ 25. PMC7226971 32326444
  8. [12]Madel MB, Ibáñez L, Wakkach A, et al. Immune function and diversity of osteoclasts in Normal and pathological conditions. Front Immunol. 2019; 10: 1408. 31275328 PMC6594198
  9. [13]Xie M, Wei J, Xu J. Inducers, attractors and modulators of CD4(+) Treg cells in non‐small‐cell lung cancer. Front Immunol. 2020; 11: 676. 32425930 PMC7212357
  10. [15]Hao Y, Hao S, Andersen‐Nissen E, et al. Integrated analysis of multimodal single‐cell data. Cell. 2021; 184: 3573‐ 3587.e3529. 34062119 PMC8238499
  11. [16]Korsunsky I, Millard N, Fan J, et al. Fast, sensitive and accurate integration of single‐cell data with harmony. Nat Methods. 2019; 16: 1289‐ 1296. 31740819 PMC6884693
  12. [17]Kim N, Kim HK, Lee K, et al. Single‐cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020; 11: 2285. 32385277 PMC7210975
  13. [18]Azizi E, Carr AJ, Plitas G, et al. Single‐cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018; 174: 1293‐ 1308.e1236. 29961579 PMC6348010
  14. [19]Aliprantis AO, Ueki Y, Sulyanto R, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 2008; 118: 3775‐ 3789. 18846253 PMC2564610
  15. [20]Zhang X, Ge R, Chen H, et al. Follicular helper CD4(+) T cells, follicular regulatory CD4(+) T cells, and inducible Costimulator and their roles in multiple sclerosis and experimental autoimmune encephalomyelitis. Mediators Inflamm. 2021; 2021: 2058964. 34552387 PMC8452443
  16. [21]Efremova M, Vento‐Tormo M, Teichmann SA, Vento‐Tormo R. CellPhoneDB: inferring cell‐cell communication from combined expression of multi‐subunit ligand‐receptor complexes. Nat Protoc. 2020; 15: 1484‐ 1506. 32103204
  17. [22]Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA‐seq data. BMC Bioinform. 2013; 14: 7. PMC3618321 23323831
  18. [23]Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015; 1: 417‐ 425. 26771021 PMC4707969
  19. [24]Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27: 1739‐ 1740. 21546393 PMC3106198
  20. [25]Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue‐infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17: 218. 27765066 PMC5073889
  21. [26]Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PloS One. 2014; 9: e107468. 25229481 PMC4167990
  22. [27]Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA‐sequencing and microarray studies. Nucleic Acids Res. 2015; 43: e47. 25605792 PMC4402510
  23. [28]Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein‐protein networks, and functional characterization of user‐uploaded gene/measurement sets. Nucleic Acids Res. 2021; 49: D605‐ D612. 33237311 PMC7779004
  24. [29]Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13: 2498‐ 2504. 14597658 PMC403769
  25. [30]Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub‐networks from complex interactome. BMC Syst Biol. 2014; 8(Suppl 4): S11. 25521941 PMC4290687
  26. [31]Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997; 16: 385‐ 395. 9044528
  27. [32]Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018; 34: 3771‐ 3772. 29790900
  28. [33]Robin X, Turck N, Hainard A, et al. pROC: an open‐source package for R and S+ to analyze and compare ROC curves. BMC Bioinformat. 2011; 12: 77. PMC3068975 21414208
  29. [34]Yang C, Tian Y, Zhao F, et al. Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci. 2020; 21: 1‐ 17. PMC7582690 32977425
  30. [35]Jovic D, Liang X, Zeng H, Lin L, Xu F, Luo Y. Single‐cell RNA sequencing technologies and applications: a brief overview. Clin Transl Med. 2022; 12: e694. 35352511 PMC8964935
  31. [36]Suvà ML, Tirosh I. Single‐cell RNA sequencing in cancer: lessons learned and emerging challenges. Mol Cell. 2019; 75: 7‐ 12. 31299208
  32. [37]Thind AS, Monga I, Thakur PK, et al. Demystifying emerging bulk RNA‐Seq applications: the application and utility of bioinformatic methodology. Brief Bioinform. 2021; 22: 1‐ 16. 34329375
  33. [38]Chen Z, Yang X, Bi G, et al. Ligand‐receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma. Int J Biol Sci. 2020; 16: 2205‐ 2219. 32549766 PMC7294944
  34. [39]Qin G, Wu X. Hsa_circ_0032463 acts as the tumor promoter in osteosarcoma by regulating the miR‐330‐3p/PNN axis. Int J Mol Med. 2021; 47: 1‐ 14. PMC8012025 33786605
  35. [40]Jiang J, Liu C, Xu G, et al. CCT6A, a novel prognostic biomarker for Ewing sarcoma. Medicine. 2021; 100: e24484. 33530265 PMC7850773
  36. [41]Ying Z, Tian H, Li Y, et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF‐β signaling. J Clin Invest. 2017; 127: 1725‐ 1740. 28375158 PMC5409794
  37. [42]Zeng G, Wang J, Huang Y, et al. Overexpressing CCT6A contributes to cancer cell growth by affecting the G1‐to‐S phase transition and predicts a negative prognosis in hepatocellular carcinoma. Onco Targets Ther. 2019; 12: 10427‐ 10439. 31819524 PMC6890186
  38. [43]Tang J, Chen H, Wong CC, et al. DEAD‐box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients. Oncogene. 2018; 37: 3006‐ 3021. 29535419 PMC5978808
  39. [44]Chang X, Jian L. LncRNA ZFPM2‐AS1 drives the progression of nasopharyngeal carcinoma via modulating the downstream miR‐3612/DTL signaling. Anticancer Drugs. 2022; 33: 523‐ 533. 35276693
  40. [45]Chen YC, Chen IS, Huang GJ, et al. Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells. Onco Targets Ther. 2018; 11: 1601‐ 1616. 29606879 PMC5868578
  41. [46]Landau DA, Tausch E, Taylor‐Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526: 525‐ 530. 26466571 PMC4815041
  42. [47]Ntoufa S, Gerousi M, Laidou S, et al. RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia. Blood Adv. 2021; 5: 2788‐ 2792. 34251413 PMC8288675
  43. [48]Kiesel JR, Buchwald ZS, Aurora R. Cross‐presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol. 2009; 182: 5477‐ 5487. 19380796
  44. [49]Grassi F, Manferdini C, Cattini L, et al. T cell suppression by osteoclasts in vitro. J Cell Physiol. 2011; 226: 982‐ 990. 20857429
  45. [50]Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen‐presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010; 116: 210‐ 217. 20304810 PMC2910608
  46. [51]Granito A, Muratori L, Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021; 27: 2994‐ 3009. 34168403 PMC8192285
  47. [52]St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020; 30: 695‐ 704. 32624246
  48. [53]Mellet J, Tshabalala M, Agbedare O, Meyer P, Gray CM, Pepper MS. Human leukocyte antigen (HLA) diversity and clinical applications in South Africa. S Afr Med J. 2019; 109: 29‐ 34. 31662146
  49. [54]Madden K, Chabot‐Richards D. HLA testing in the molecular diagnostic laboratory. Virchows Archiv. 2019; 474: 139‐ 147. 30515565

Cited by

Sorted by citations

Authors
Li, F., Tang, H., Luo, X., Li, X., Luo, K., Liu, S., Liang, J., Liao, S., Zhong, C., Zhan, X., Wei, Q., Feng, W., & Liu, Y.
Affiliations
  • Guangxi Medical University (CN)
  • First Affiliated Hospital of GuangXi Medical University (CN)
Corresponding author
  • Feng, Wenyu
  • Liu, Yun
ORCID
Venue
Cancer Science
Publisher
Wiley
Published
2023-05-07
Volume
114
Issue
7
Pages
3014-3026
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
DOI
10.1111/cas.15821
PMC
PMC10323104
OpenAlex
W4375855833
Cited by
22
References
5
Citations by year
2026: 2 · 2025: 11 · 2024: 7 · 2023: 2
FWCI
4.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Science (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81960768, 82260814)
  • Natural Science Foundation of Guangxi Province (2020GXNSFAA259088)
  • Youth Science Foundation of Guangxi Medical University (GXMUYSF202129, GXMUYSF202313)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
Keywords
osteosarcoma, osteoclasts, CD4+ regulatory T cells, tumor microenvironment, intercellular communication, prognostic gene signature, survival prediction, protein-protein interaction network, single-cell RNA sequencing, consensus clustering
MeSH terms
Bone Neoplasms, Humans, Osteoclasts, Prognosis, Osteosarcoma, T-Lymphocytes, CD4-Positive T-Lymphocytes, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review